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Abstract 
 
Airway remodeling including increased airway smooth muscle (ASM) mass is a hallmark 
feature of asthma and COPD. We previously identified the expression of bitter taste receptors 
(TAS2Rs) on human ASM cells, and demonstrated that known TAS2R agonists could promote 
ASM relaxation and bronchodilation, and inhibit mitogen-induced ASM growth. In this study we 
explored cellular mechanisms mediating the anti-mitogenic effect of TAS2R agonists on human 
ASM cells. Pre-treatment of ASM cells with TAS2R agonists, chloroquine and quinine, resulted 
in inhibition of cell survival, which was largely reversed by bafilomycin A1. Transmission 
electron microscope studies demonstrated the presence of double-membrane autophagosomes 
and deformed mitochondria. In ASM cells, TAS2R agonists decreased mitochondrial membrane 
potential, increased mitochondrial ROS and mitochondrial fragmentation. Inhibiting dynamin-
like protein (DLP1) reversed TAS2R agonist-induced mitochondrial membrane potential change, 
and attenuated mitochondrial fragmentation and cell death. Consistent with these findings, the 
expression of mitochondrial protein BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
(Bnip3) and mitochondrial localization of DLP1 were significantly up-regulated by TAS2R 
agonists. More importantly, inhibiting Bnip3 mitochondrial localization by dominant-negative 
Bnip3 significantly attenuated cell death induced by TAS2R agonist. Collectively, TAS2R 
agonists, chloroquine and quinine modulate mitochondrial structure and function resulting in 
ASM cell death. Furthermore, Bnip3 plays a central role in TAS2R agonist-induced ASM 
functional changes via a mitochondrial pathway. These findings further establish the cellular 
mechanisms of anti-mitogenic effects of TAS2R agonists, and identify a novel class of receptors 
and pathways that can be targeted to mitigate airway remodeling as well as bronchoconstriction 
in obstructive airway diseases.   
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INTRODUCTION 
 Airway inflammatory diseases such as asthma and COPD are characterized by 
inflammation, mucus production, airway remodeling and hyperresponsiveness resulting in severe 
bronchoconstriction (4, 27, 45). The chronic nature of these diseases leads to structural and 
functional changes in resident cells of the airway wall including ASM cells (27, 28, 39, 40). 
Histological evaluation of asthmatic lung samples reveals a significant increase in the ASM mass 
(8, 17, 19, 25), which is correlated with asthma severity (2, 15, 55). Alterations in ASM mass 
and phenotype are now appreciated as pathogenic mechanisms of obstructive lung diseases (6). 
 G protein-coupled receptor (GPCR) signaling plays a vital role in the regulation of ASM 
contraction, relaxation, and proliferation (4, 10) and therefore, agonists/antagonists of GPCRs 
represent potentially efficacious anti-asthma medications. Current anti-asthma therapies, 
including beta-agonists and corticosteroids, aim at alleviating bronchoconstriction and 
inflammation, respectively, but have a very limited effect on remodeling (4). Thus there is a 
pressing need for identifying new drugs that cause both ASM relaxation and inhibition of 
growth. 
Recently we identified the expression of type II taste receptors (TAS2Rs) on human 
ASM cells and characterized intracellular signaling mediated via these receptors using a panel of 
known TAS2R agonists (12, 50). Among the 25 known taste receptors at least three subtypes are 
highly expressed (T2R10, T2R14, T2R31) and three more are moderately expressed (T2R5, 
T2R4, T2R19) in human ASM. Expression of TAS2Rs on guinea pig and murine ASM has also 
been demonstrated recently (34, 47). Extant TAS2R agonists include both synthetic and natural 
compounds. One group includes chloroquine and quinine, which activate T2R10, T2R14, and 
T2R31 expressed on human ASM cells (12, 35). Stimulation of ASM cells with TAS2R agonists 
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resulted in an increase in intracellular calcium that was GEJ, PLC- and IP3-dependent. 
Interestingly, elevation of calcium upon TASR stimulation was associated with a robust 
relaxation of ASM cells and airway rings. This relaxation effect of TAS2R agonists was 
confirmed by three independent laboratories using mouse, guinea pig and human airways (12, 
34, 47). Studies using lung slices (human and murine) and in vivo aerosol challenge in murine 
models have demonstrated efficacious bronchodilation by TAS2R agonists. These observations 
posit TAS2R agonists as a new class of bronchodilators for clinical use. Recent study from our 
laboratory demonstrated that TAS2R agonists such as chloroquine and quinine inhibit mitogen-
induced human ASM growth (50). Furthermore, the anti-mitogenic effect of TAS2R agonist is 
mediated, at least partially, via inhibition of PI3 kinase pathway and arresting of cell cycle 
progression (50). 
Increases in ASM mass could result from multiple mechanisms including an increase in 
cell number (hyperplasia), size (hypertrophy), epithelial to mesenchymal transition (EMT), or 
decrease in cell death. Inhibition of ASM growth by anti-mitogenic agents can occur via 
targeting of any of these mechanisms including autophagy and mitochondrial-initiated cell death. 
In this study we aimed to determine additional cellular mechanisms involved in the anti-
mitogenic effect of TAS2R agonists, chloroquine and quinine on human ASM cells. Using 
advanced microscopic imaging and biochemical tools herein we demonstrate that TAS2R 
agonists modulate mitochondria dynamics and function leading to ASM cell death. Chloroquine- 
and quinine-induced ASM cell death was reversed by pre-treating cells with befilomycin A1, an 
autophagy inhibitor, suggesting the role of autophagy. Interestingly, the anti-mitogenic effect of 
TAS2R agonists on human ASM cells was attenuated by inhibiting Bnip3, a mitochondrial 
protein, using dominant negative Bnip3 or a DLP1 inhibitor Mdivi-1, suggesting a central role 
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for mitochondrial protein Bnip3 and autophagy in TAS2R agonist-mediated anti-mitogenic effect 
on human ASM. 
METHODS 
Materials 
Antibodies against Mfn1, Mfn2, and Bnip3 were from Abcam (Burlinggame, CA, USA). 
DLP1 and Opa1 antibodies were from BD Bioscience (Franklin Lakes, NJ, USA). VDAC, 
Beclin-1 and ATG-5 antibody were purchased from Cell Signaling Technology (Beverly, MA, 
USA). IRDye 680 or 800 secondary antibodies were from Rockland (Gilbertsville, PA, USA). 
Quantitative PCR arrays and SYBR green reagents were purchased from Qiagen (Valencia, CA, 
USA). MTT cell proliferation assay kit, MitoTracker Green and MitoSox red are from Thermo 
Fisher Scientific (Pittsburg, PA, USA). siRNA oligos were obtained from Dharmacon (Lafayette, 
CO, USA). Rabbit-anti LC3-β, anti-E-actin, Bafilomycin A1 (Baf A1), 3-Methyl adenine (3-
MA), chloroquine, quinine, saccharine, and other reagents were obtained from Sigma (St. Louis, 
MO, USA) or from previously identified sources (12, 50). Wild type and dominant-negative 
Bnip3 adeno-associated virus were from ViGene Bioscience (Rockville, MD, USA) 
Cell culture 
Human ASM cultures were established from human tracheae or primary bronchi using 
enzyme dissociation method, and were grown in F-12 medium with supplements as described 
previously (11, 12, 37). ASM cells in subculture during the second through fifth cell passages 
were used. The cells were maintained in F-12 medium with no serum and supplemented with 1% 
insulin transferrin selenium (arresting medium) for 24-48 h before the experiments.  
Isolation of mitochondria 
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Mitochondria were isolated from ASM cells after the treatments with TAS2R agonists 
using Mitochondria Isolation Kit (Miltenyi Biotec) (21, 36). Briefly, 1x107 ASM cells were 
collected, washed with PBS and resuspended in 1 ml lysis buffer. Cell homogenates were 
prepared using a dounce homogenizer and incubated with 50 Pl of anti-Tom22 coated beads for 
1 h with gentle shaking at 4°C. After the non-specific binding was washed out in the magnetic 
field, mitochondria were isolated for analysis.  
siRNA transfection and viral (Adeno-Associated Virus, AAV) infection  
 siRNA transfection was performed in human ASM cells as described previously (49). 
Briefly, cells were seeded in 6-well plates one day before transfection. Transfection mixture was 
prepared by adding 2-5 μl of 5 μM siRNA and 5 μl DharmaFECT1 (GE Healthcare) reagent to 
serum-free medium. After incubating at room temperature for 20 min the mixture was transferred 
to a new tube containing 1 ml of complete medium (final siRNA concentration was 25 nM) and 
transferred to cells after 5 min. AAV infection was performed according to the manufacturer’s 
instruction (ViGene Bioscience). Briefly, cells were seeded on a 6-well plate one day before the 
infection. On the following day, cells were infected with 105/cell AAV particles expressing 
either wild type or dominant-negative (DN) Bnip3. After 12 h incubation, virus-containing media 
was replaced with regular culture media. The success in infection was monitored by green 
fluorescence protein (GFP) expression using a fluorescence microscope. For confocal studies, 
cells were cultured on confocal dishes, serum starved and treated with TAS2R agonists for 24 h 
before propidium iodide (PI) staining was performed. 
Propidium iodide (PI) staining 
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Human ASM cells were incubated with 4 Pl of PI (10 mg/ml) in 1 ml of medium in a 
CO2 incubator. The staining solution was removed after 5 min followed by three washes with 
PBS. ASM cell images were acquired using a confocal (λex 535 nm, λem 617 nm) microscope.   
MTT and CyQuant assay  
MTT and CyQuant assays were performed as described previously (50). Human ASM 
cells were grown to sub-confluence in 96-well cell culture plates before switching to growth 
arrest media for 24 h (F12 + 1% ITS) and then treated with TAS2R agonists in the presence or 
absence of PDGF (10 ng/ml) for 24 h. In some cases cells were pretreated with 3 PM Mdivi-1 for 
2 h before treating with TAS2R agonists ± PDGF. At the end of the treatment, media was 
removed and cells incubated with MTT or CyQuant reagent for 4 h or 1 h respectively, and 
absorbance or fluorescence determined using a plate reader.  
Immunostaining and light microscope imaging 
Cells were plated onto pre-cleared glass coverslips in 6-well culture dishes and fixed for 
15 min at 4°C in 3% paraformaldehyde (PFA) and then permeabilized by incubation for 5 min at 
4°C using 3% PFA and 0.3% Triton X-100. Fixed cells were first blocked for 2 h at room 
temperature in cyto-TBS buffer containing 1% BSA and 2% normal donkey serum. Incubation 
with primary antibody rabbit anti-LC3EII (1:100) occurred overnight at 4°C in cyto-TBST 
followed by FITC-conjugated secondary antibody. For negative controls, cells were incubated 
with either isotype-matched mouse IgG or rabbit antiserum. Coverslips were mounted using 
ProLong antifade medium (Molecular Probes, Inc. USA). Fluorescent imaging of LC3 was 
performed by capturing a mid-cell section of 0.3 μm focal depth using an Olympus LX-70 
FluoView Confocal Laser Scanning Microscope (Olympus America Inc, Melville, N.Y.) 
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equipped with a 40x objective. Brightfield images were acquired to assess the morphology of the 
cell with treatment protocol. 
Electron microscopy (EM) studies 
The ultrastructural details of the cell were assessed using transmission electron 
microscopy (TEM) to measure autophagosome formation and assess mitochondrial integrity 
(46). Cells were grown in 6-well culture plates, treated as described above and processed further 
for Transmission Electron Microscopy.  Imaging was performed at the core facility at University 
of Maryland, Baltimore using FEI Tecnai T12 high-resolution microscope.  
Western blotting 
Western blotting (immunoblotting) was performed as described previously (42, 43). The 
images were acquired by Odessey image scanner (LiCor). Equal loading of protein was ensured 
by determining the expression of E-actin or tubulin.  
RNA isolation, RT-PCR and Real-Time PCR array 
Cells grown on 6-well plates were treated with PDGF or vehicle with or without 
pretreatment with TAS2R agonists for 24 h, and total RNA was harvested as described in our 
previous studies (37, 50). Total RNA (1 Pg) was converted to cDNA by RT reaction and the 
reaction stopped by heating the samples at 94oC for 5 min. Quantitative real-time PCR was 
performed using RT2 Profiler PCR Array for mitochondria genes (PAHS-087Z) using Applied 
Biosystems real time PCR machine (Mx3005). Raw Ct values were obtained using software 
recommended threshold fluorescence intensity. Gene expression data was calculated as described 
previously using expression of internal control gene (GAPDH) (12, 49).  
Assessment of Mitochondrial Membrane Potential and Reactive Oxygen Species (ROS) 
generation 
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Mitochondrial membrane potential and ROS measurements were performed as described 
previously (43). Briefly, after the treatment with TAS2R agonists, ASM cells were incubated 
with mitochondrial membrane potential dye Tetramethylrhodamine, ethyl ester (TMRE) or 
mitochondrial ROS probe MitoSox red for 30 min, then washed with PBS to remove the 
unincorporated dyes. Mitochondrial membrane potential and ROS generation were monitored by 
live-cell imaging using a confocal microscope. Mitochondria images were acquired by Fluoview 
(Olympus) using a 60x Oil objective and analyzed using NIH ImageJ 1.44 software. 
Statistical analyses 
Data are presented as mean ± SEM values from at least three experiments, in which each 
experiment was performed using a different ASM culture derived from a unique donor. 
Individual data points from a single experiment were calculated as the mean value from three 
replicate observations, and reported as fold change from vehicle treated group. Statistically 
significant differences among groups were assessed by either student t-test or ANOVA using 
Prism Graphpad software (Graphpad, La Jolla, CA, USA), with values of p<0.05 sufficient to 
reject the null hypothesis. 
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RESULTS 
TAS2R agonists induce ASM cell death  
We used PDGF to induce ASM growth and determined the effect of three different 
TAS2R agonists chloroquine (Chloro), quinine (Quin) and saccharin (Sacc) on mitogen-induced 
ASM growth. ASM cell survival was significantly decreased by chloroquine and quinine (Figure 
1A) supporting the anti-mitogenic effect of TAS2R agonists on human ASM cells (50). 
Saccharine, a relatively weak TAS2R agonist, caused a modest inhibition of ASM growth that 
was not statistically different from vehicle-pretreated control. Further, human ASM cells were 
pre-treated with autophagy inhibitor, Baf A1, followed by TAS2R agonists. Baf A1 mitigated 
cell death-inducing effect of chloroquine and quinine on human ASM cells (Figure 1A-B) 
suggesting a potential role of autophagy. Induction of autophagy in human ASM by chloroquine 
and quinine was further confirmed by immunofluorescence and immunoblot detection of LC3E 
puncta formation and LC3E,, accumulation, respectively.  LC3E accumulation in human ASM 
cells was significantly reduced in the presence of Baf A1 and 3-methyl adenine (3MA) (Figure 
1C and 1D). Transmission electron microscopy revealed accumulation of double-membrane 
autophagosomes, vesicles and deformed mitochondria in human ASM cells upon treatment with 
TAS2R agonists, chloroquine and quinine in the presence of PDGF (Figure 1E). Collectively, 
these findings suggest the involvement of autophagy in TAS2R agonist-mediated anti-mitogenic 
effect on human ASM cells.    
TAS2R agonists impair mitochondrial function in human ASM cells 
Our TEM studies demonstrated that chronic treatment of human ASM cells with TAS2R 
agonists increased accumulation of deformed mitochondria (Figure 1E). Therefore, we next 
assessed whether mitochondrial function was altered by TAS2R agonists. Indeed, the 
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mitochondrial membrane potential was significantly decreased after exposure to TAS2R agonists 
compared to vehicle treated cells (4078.89r255.77, chloro+PDGF; 16389.80r973.86, 
quin+PDGF; and 44871.11r1159.62 vehicle controls; p<0.05, n=9) (Figure 2A). Because 
mitochondrial membrane potential is the primary drive for ATP synthesis (13, 24), we further 
examined cellular ATP levels in ASM cells exposed to chloroquine and quinine. TAS2R agonists 
significantly decreased cellular ATP levels compared to vehicle-treated controls (0.62r0.03 fold 
basal for chloro+PDGF; and 0.74r0.14 fold basal for quin+PDGF; p<0.05, n=3) (Figure 2B). 
Further, mitochondrial ROS levels in human ASM cells were significantly increased by TAS2R 
agonists (5128.66r104.51 chloro+PDGF; 2982.24r254.28 quin+PDGF; and 2467.8r356.44 
vehicle-treated controls; n=24, p<0.05) (Figure 2C). Collectively, these data strongly suggest that 
chronic exposure of human ASM cells to TAS2R agonists, chloroquine or quinine results in 
mitochondrial dysfunction as indicated by a significant decrease in mitochondrial membrane 
potential, cellular ATP levels, and a significant increase in mitochondrial ROS.  
TAS2R agonists increase mitochondrial fragmentation in human ASM cells 
To further understand the subcellular effect of TAS2R agonists in human ASM cells, we 
determined the effect of chloroquine and quinine on mitochondrial dynamics. In control cells 
exposed to vehicle, mitochondria were interconnected and formed tubular and granular network. 
Exposure of cells to TAS2R agonists caused an increase in fragmented mitochondria as 
determined by live-cell confocal imaging (Figure 3A). The mitochondrial morphology data were 
further analyzed quantitatively using form factor (an indicator of mitochondria branching) and 
aspect ratio (an indicator of mitochondria length). Chloroquine and quinine significantly 
increased mitochondrial fragmentation (Figure 3A-C). The mitochondrial branches were 
significantly decreased by the exposure of ASM cells to chloroquine plus PDGF (2.40r0.08, 
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n=5, p<0.05) or quinine plus PDGF (2.26r0.08, n=5, p<0.05) compared to vehicle control 
(3.92r0.19) (Figure 3B).  Similarly, compared to vehicle control (3.89r0.15), chloroquine or 
quinine plus PDGF significantly decreased length of mitochondria (2.1r0.06 and 2.65r0.09 
respectively, n=5, p<0.05) (Figure 3C). Interestingly, exposure of human ASM cells to TAS2R 
agonists did not significantly change expression levels of mitochondrial dynamics proteins 
including dynamin-like protein 1 (DLP1), optic atrophy 1 (Opa1), mitofusin 1 (Mfn1) and 
mitofusin 2 (Mfn2) indicating the alteration in mitochondrial dynamics is not due to the changes 
in the expression levels of the mitochondrial dynamic proteins (Figure 3D). These data suggest 
that chronic exposure of human ASM cells to chloroquine and quinine alters mitochondrial 
dynamics leading to mitochondrial fragmentation.  
TAS2R agonists increase Bnip3 expression and DLP1 mitochondrial localization in human 
ASM cells  
To determine the molecular mechanisms by which chloroquine and quinine change 
mitochondrial dynamics and function, we performed RT2 profiler PCR Array analysis (Figure 4). 
Real-time PCR analysis revealed significant upregulation of Bnip3 expression in human ASM 
cells exposed to chloroquine and quinine (1.59r0.05 and 2.41r0.07 fold control, chloro or 
quin+PDGF respectively; p<0.05, n=4) (Figure 4A-B).  
To explore the molecular mechanisms by which chloroquine and quinine alter 
mitochondria morphology and function, we isolated mitochondria from human ASM cells 
exposed to TAS2R agonists. Western blotting of lysates from isolated mitochondria 
demonstrated significantly increased levels of DLP1 in the mitochondrial fraction upon treatment 
with chloroquine or quinine plus PDGF compared to vehicle controls (Figure 4C-D). There was 
no significant change in the protein levels of other mitochondrial proteins such as (voltage-
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dependent anion channel) VDAC (Figure 4C bottom panel). Other studies have demonstrated 
that Bnip3 increases DLP1 in mitochondria (29). Our data support a model in which TAS2R 
agonists up-regulate Bnip3 expression, which increases DLP1 levels in mitochondria resulting in 
mitochondrial fragmentation and dysfunction.  
Bnip3 siRNA partly reverses TAS2R agonists-induced mitochondrial fragmentation 
To confirm the role of Bnip3 in TAS2R-induced mitochondrial fragmentation, we down-
regulated Bnip3 in human ASM cells using a siRNA approach. Transfection of human ASM 
cells with Bnip3 siRNA significantly decreased Bnip3 levels without affecting other 
mitochondrial proteins such as Opa1 (Figure 5A-B). More importantly, transfection with Bnip3 
siRNA partly reversed mitochondrial fragmentation induced by chloroquine or quinine plus 
PDGF, as indicated by confocal imaging as well as the analysis of form factors and aspect ratio 
(Figures 5C-E). In Bnip3 siRNA transfected human ASM cells, mitochondrial branches and 
length were significantly increased compared to control siRNA transfected cells (Figure 5C-E). 
Down-regulation of Bnip3 expression by siRNA did not have significant effects on the protein 
levels of DLP1 (data not shown). These data strongly suggest that Bnip3 plays a role in TAS2R 
agonists-induced mitochondrial fragmentation. However, current siRNA/shRNA approaches 
(that work in primary ASM) are not amenable to analyses of ASM growth and we were not able 
to demonstrate the role of Bnip3 in the regulation of ASM growth by TAS2R agonists. 
Therefore, we used additional approaches to down-regulate mitochondrial Bnip3 levels. 
Dominant-negative Bnip3 inhibits TAS2R agonists-induced cell death in human ASM cells 
We have demonstrated that TAS2R agonists-induced increase in mitochondrial 
fragmentation and cell death in human ASM cells is associated with increased Bnip3 expression. 
To further understand the role of Bnip3 in TAS2R agonists-induced mitochondrial fragmentation 
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and cell death in ASM cells, we generated adeno-associated virus (AAV) expressing wild type 
(WT) or dominant-negative (DN) Bnip3 lacking the c-terminal mitochondrial localization 
domain. The truncated Bnip3 does not localize to mitochondria, and functions as the dominant-
negative form of Bnip3. The infection efficiency was determined by GFP-fluorescence (Figure 
6A). The expression of WT and DN Bnip3 was confirmed by western blotting (Figure 6B). 
Using this approach, we determined the role of Bnip3 in TAS2R agonists-induced cell death in 
Bnip3 expressing human ASM cells (Figure 6C). TAS2R agonists-induced cell death was 
significantly decreased in human ASM cells transfected with DN-Bnip3 compared to cells 
transfected with WT-Bnip3 (a 66% decrease in chloro+PDGF group and a 73% decrease in 
quin+PDGF group, n=4; p<0.01 for both). These findings demonstrate that TAS2R agonists-
induced ASM cell death is mediated via Bnip3 localization to mitochondria and mitochondrial 
mechanisms. 
Inhibition of mitochondrial fission by DLP1 inhibitor Mdivi-1 attenuates TAS2R agonists-
induced mitochondrial fragmentation, decrease in mitochondrial membrane potential, and cell 
death in human ASM cells  
Our data suggest that chronic exposure of human ASM cells to TAS2R agonists increases 
mitochondrial fragmentation. Because excessive mitochondrial fission causes mitochondrial 
depolarization and cell death (58), (23), we hypothesized that inhibition of mitochondrial fission 
using DLP1 inhibitor, Mdivi-1, would rescue loss of mitochondrial functions and cell death 
induced by TAS2R agonists. Pre-incubation of ASM cells with 3 PM Mdivi-1 for 2 h, a well-
established inhibitor of DLP1, decreased chloroquine- and quinine- induced mitochondrial 
fragmentation (Figure 7A). Mdivi-1 pre-treatment significantly reversed the decrease in 
mitochondrial membrane potential induced by TAS2R agonists (69% increase vs chloro+PDGF; 
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and 62.1% increase vs quin+PDGF; n=10; p<0.05 for both) (Figure 7B). Further, pretreatment 
with Mdivi-1 significantly decreased TAS2R agonists-induced cell death (Figure 7C-D) (30% 
increase in cell survival vs chloro+PDGF; and 35.4% increase vs quin+PDGF; n=3, p<0.05 for 
both) (Figure 7D). These data suggest that TAS2R agonists increase mitochondrial DLP1 
accumulation leading to mitochondrial fragmentation and cell death. 
DISCUSSION 
In this study, we established that chronic exposure of human ASM cells to TAS2R 
agonists, chloroquine and quinine inhibit human ASM cell survival via Bnip3 up-regulation, 
DLP-1-mediated mitochondrial fragmentation, and mitochondrial dysfunction (as indicated by 
decreased mitochondrial membrane potential, cellular ATP levels and increased mitochondrial 
ROS) leading to initiation of autophagy. Inhibition of mitochondrial fission attenuated the 
decrease in mitochondrial membrane potential and decreased TAS2R agonists-induced ASM cell 
death. Further, inhibition of Bnip3 mitochondrial localization by expressing dominant-negative 
Bnip3 increased human ASM cell survival upon exposure of TAS2R agonists. Our data support a 
model in which TAS2R agonists inhibit ASM cell survival via Bnip3-mediated mitochondria-
dependent mechanism of initiating autophagy (Figure 8). 
Autophagy causes proteolytic degradation of cytosolic components. There are three types 
of autophagy: macro-autophagy, micro-autophagy, and chaperone-mediated autophagy. All these 
three processes degrade cytosolic components at the lysosomes (38). This is mediated by a 
special organelle called autophgosome. Autophagic process consists of several sequential steps 
including sequestration, degradation and amino acid generation. Autophagy is active in most of 
the cells in the body at basal level to remove damaged organelles and proteins. However, 
autophagy can also be stimulated in stress situation such as nutrient depletion. During nutrient 
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shortage, autophagy provides the constituents required for survival. Autophagy is an 
evolutionary conserved process to maintain the energy balance (30, 32, 44). Recent studies have 
demonstrated that autophagy plays a role in a variety of physiological and pathological processes 
besides adaptation to starvation such as development, aging, cancer and muscle disorder (38). 
Autophagic removal of damaged proteins, organelles including mitochondria, endoplasmic 
reticulum, peroxisomes serves as an important quality control mechanism for cell survival (16). 
The regulation of autophagy in mammals is very complicated and involves multiple signaling 
pathways (5) (41) (7). Dysregulation of autophagy is linked to cell death (9, 33). For example, 
accumulation of ATGs has been found in mammalian cells undergoing autophagic cell death, 
which requires the presence of Bcl-2 family proteins (51). Furthermore, excessive autophagy in 
cells has been shown to induce cell death (9, 33). Our findings in this study demonstrate that 
chloroquine and quinine mediated cell death in human ASM cells involves autophagy.  
Mitochondria are highly dynamic organelles that undergo fission and fusion constantly. 
Mitochondrial fission and fusion are the key determinants of mitochondria morphology and 
function (20). Through fission and fusion mechanisms, mitochondria change their length and 
number. In addition, fission and fusion allow mitochondria to exchange lipid membranes and 
intra-mitochondrial substance. Such an exchange is essential for maintaining healthy 
mitochondria population. The shape of the mitochondria is important for the distribution of 
mitochondria especially in highly polarized cells such as neurons. Excessive mitochondria 
fission facilitates cell death and the release of inter membrane space substances (31, 56, 57). 
Mitochondria become elongated when fusion is dominant or fission is insufficient. In contrast, 
enhanced fission or insufficient fusion causes fragmented mitochondria. A well-balanced fission 
and fusion is essential for mitochondria health and function. Altered mitochondrial dynamics is 
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found in human diseases and aging (1, 3, 20, 31, 53, 56, 57). Treatment of human ASM cells 
with chloroquine and quinine resulted in an increased mitochondrial fission leading to 
accumulation of fragmented mitochondria and loss of mitochondrial functions.  
Mitochondrial fission and fusion are tightly controlled by mitochondrial dynamic 
machineries. Opa1, Mfn1 and Mfn2 are the key mitochondrial fusion machineries (3, 31). DLP1 
is indispensible for mitochondrial fission. DLP1 deletion causes an increase in elongated 
mitochondria. In contrast, increased mitochondrial DLP1 levels leads to mitochondrial 
fragmentation (22, 52). Our data support a key role for DLP1 in the regulation of mitochondrial 
dynamics in response to TAS2R agonist treatment. Increased mitochondrial fragmentation in 
cells exposed to TAS2R agonists indicates a shift in the balance between fission and fusion 
likely due to enhanced mitochondrial localization of DLP1. The key role of DLP1-mediated 
mitochondrial fission in TAS2R agonist-induced cell death was further demonstrated by 
experiments using DLP1 inhibitor Mdivi-1. Mdivi-1 inhibited TAS2R agonist-induced 
mitochondrial fission, reversed mitochondrial membrane potential, and attenuated ASM cell 
death.   
In this study, we also demonstrated that TAS2R agonists up regulate expression of Bnip3 
and regulate DLP1 translocation to mitochondria. Our data are consistent with recent studies 
showing that Bnip3 causes DLP1 mitochondrial localization and mitochondrial fragmentation 
(29). Bnip3 was originally identified as a BH3-only proapoptotic protein of Bcl-2 family 
inducing mitophagy and mitochondria-mediated cell death. It localizes to the mitochondrial outer 
membrane and induces mitochondria-initiated cell death through modulation of outer 
mitochondria membrane permeabilization (26, 48). The expression of Bnip3 is inducible. For 
example, in cardiac tissues, Bnip3 expression is increased by hypoxia, and up-regulation of 
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Bnip3 is responsible for ischemia injury-induced cardiomyocyte death (14). Consistent with 
these findings, our data suggest a role for Bnip3 in TAS2R agonist-induced mitochondrial 
fragmentation and cell death. Although hypoxia-induced autophagy involves Bnip3, its role in 
the regulation of cardiomyocyte death is controversial. In an ischemia-reperfusion model, Bnip3-
induced autophagy protected myocytes from cell death (18). However, another study showed that 
Bnip3 promoted autophagic cell death (54). Interestingly, in our study, knocking down Bnip3 
partly reversed mitochondrial fragmentation but did not reverse TAS2R agonist-induced ASM 
cell death (data not shown). This presumably is because cell growth assay requires treatment 
over 72 h by which time the inhibitory effect of siRNA on Bnip3 expression was diminished. 
Alternatively, dominant-negative Bnip3, which inhibits Bnip3 mitochondrial localization 
significantly reversed TAS2R agonist-induced ASM cell death. Our data suggest that in response 
to TAS2R agonists, increased mitochondrial Bnip3 recruits more DLP1 to mitochondria leading 
to mitochondrial fragmentation and ASM cell death. 
Our previous study demonstrated that the TAS2R agonists, chloroquine and quinine 
inhibit ASM proliferation induced by FBS, PDGF, or EGF. The anti-mitogenic effects are 
largely mediated by TAS2R agonist inhibition of cell cycle progression (50).  The findings from 
the current studies demonstrate the role of mitochondria-dependent mechanisms in inhibiting 
ASM growth by TAS2R agonists. Our data suggest that Bnip3 is a mitochondrial target for the 
anti-mitogenic effect of TAS2R agonist. Additional studies are needed to determine the relative 
contribution of multiple cellular mechanisms in mediating anti-mitogenic effect of TAS2R 
agonists on human ASM cells. Collectively, these studies demonstrate the beneficial effect of 
TAS2R agonists in mitigating ASM growth, a key component of airway remodeling in asthma 
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pathogenesis, further underscoring the potential for exploring TAS2Rs as anti-asthma therapeutic 
targets.  
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Figure captions 
Figure 1. TAS2R agonists induce human ASM cell death. Human ASM cells were serum starved 
for 24 h and then treated with either vehicle or TAS2R agonists (chloro, quin and sacc) at 125 
PM in the presence of PDGF (10 ng/ml) for 24 h. A. A select set of cells were pretreated with 
autophagy inhibitors: Baflomycin A (BafA1, 20 nM), and 3-Methyl adenine (3MA, 5μM). A. 
Cell viability was measured by MTT assay (**p<0.01, ***p<0.001, n=5). B. Light scope images 
showing cells treated with vehicle control (Con), chloroquine (Chloro), Quinine (Quin), Chloro 
or Quin+PDGF and cells pre-treated with BafA1 or 3MA before the treatment with PDGF or 
Chloro or Quin. C. A select set of cells were pretreated with either Baf A1, or 3MA before the 
treatment with PDGF+Chloro or Quin. Cells were stained with anti-LC3 rabbit polyclonal 
antibody (1:100) followed by FITC-conjugated secondary antibody. Scale bars=20 μm. 
Representative confocal images are presented (n=4). D. Immunoblotting showing results 
obtained after treating cells either with Chloro or Quin or PDGF alone or Chloro or Quin+PDGF. 
Key autophagy marker proteins Beclin-1, ATG-5 and LC3E II were found to be increased by 
treatment with TAS2R agonist in presence of PDGF, results shown are representative of five 
independent experiments using five human primary ASM cells. E. TEM images (6500X mag) 
showing subcellular structural changes in ASM. Green- Vesicles; Red- autophagosome; Purple- 
mitochondria. Note accumulation of empty vesicles, double-membrane autophagosomes and 
deformed mitochondria in cells treated with TAS2R agonist in presence of PDGF. Images shown 
are representative of n=3 different experiments obtained from three primary human ASM cells. 
Figure 2. TAS2R agonists impair mitochondrial function and decrease cellular ATP levels. 
Human ASM cells were serum starved for 24 h and then treated with either vehicle or 125 PM 
TAS2R agonists (chloro and quin) in the absence and presence of 10 ng/ml PDGF (P) for 24  h. 
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A. Mitochondrial membrane potential was measured using TMRE (*p<0.05, n=9). B. Cellular 
ATP levels were measured as luciferase intensity (*p<0.05, n=3). C. Mitochondrial ROS was 
measured by confocal live-cell imaging using mitoSox red (*p<0.05, n=24).  
Figure 3. TAS2R agonists increase fragmented mitochondria. Human ASM cells were serum 
starved for 24 h and then treated with either vehicle or TAS2R agonists (chloro, quin and sacc) at 
125 PM in the absence and presence of 10 ng/ml PDGF (P) for 24 h. A. Mitochondria 
morphology was monitored by confocal live-cell imaging using MitoTracker green. Scale bar=40 
Pm. B-C. Quantitative measurement of mitochondrial morphology using form factor (B) and 
aspect ratio (C) after TAS2R agonist treatment (*p<0.05, n=5). D. Mitochondrial fission protein 
DLP1, and mitochondrial fusion protein Opa1, Mfn1, and Mfn2 levels were measured by 
Western blot. Representative blots for DLP1, Opa1, Mfn1 and Mfn2. E-actin was used as a 
loading control. 
Figure 4. TAS2R agonists increase Bnip3 gene expression and DLP1 mitochondrial localization. 
Human ASM cells were serum starved for 24 h and then treated with either vehicle or 125 PM 
TAS2R agonists (chloro and quin) in the absence and presence of 10 ng/ml PDGF (P) for 24 h. 
A. RT2 profiler PCR Array showing mitochondrial gene expression profile. B. Bnip3 expression 
levels after TAS2R agonist treatment (*p<0.05, n=4). C. Mitochondrial DLP1 and Bnip3 protein 
levels assayed by Western blot using isolated mitochondrial protein lysates. VDAC was used as 
internal control for mitochondrial proteins. D. Quantified data of C showing mitochondrial DLP1 
protein levels normalized to VDAC (*p<0.05, n=3). 
Figure 5. Bnip3 siRNA partly reverses TAS2R agonist-induced mitochondrial fragmentation. 
Human ASM cells were transfected with Bnip3 siRNA and then treated with either vehicle or 
125 PM TAS2R agonists (chloro, quin, and sacc) in the absence and presence of 10 ng/ml PDGF 
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(P) for 24 h. A-B. Bnip3 siRNA significantly decreased Bnip3 protein levels (*p<0.05, n=3). E-
actin was used as loading control. C. Representative confocal images of MitoTracker labeled 
mitochondria. Scale bar=50 Pm. D-E. Quantitative analysis of mitochondria images using form 
factor (D) and aspect ratio (E),  *p <0.05, n=4. 
Figure 6.  Dominant-negative Bnip3 inhibits TAS2R agonist-induced human ASM cell death. 
Wild type and dominant-negative Bnip3 were transiently expressed in human ASM cells. After 
serum starvation for 24 h, cells were treated with vehicle, PDGF, or 125 PM TAS2R agonists 
(chloro or quin) in the presence of 10 ng/ml PDGF (P) for 24 h. GFP and PI positive cells were 
recorded by confocal imaging. A. Representative confocal images indicating the live (GFP 
positive, green) as well as dead (PI positive, red) cells. B. Representative Western blot 
confirming the successful expression of wild type Bnip3 (WT) and dominant-negative Bnip3 
(DN-Bnip3) in human ASM cells. C. Human ASM cell survival assay measured by PI staining.  
Figure 7.  Inhibition of mitochondrial fission by Mdivi-1 increased mitochondrial membrane 
potential and decreased TAS2R agonist-induced cell death. Human ASM cells were serum 
starved for 24 h and pre incubated with either vehicle or 3 PM Mdivi-1 for 2 h. Following the 
incubation of vehicle or Mdivi-1, cells were treated with vehicle, PDGF, or 125 PM TAS2R 
agonists (chloro or quin) in the presence of 10 ng/ml PDGF (P) for 24 h. A. confocal live-cell 
imaging showing mitochondrial labeled with MitoTracker Green. B. Mitochondrial membrane 
potential as measured by TMRE fluorescence (n=10 *p<0.05). C. Representative light scope 
images of human ASM cells 24 h after treatment. D. Human ASM cell viability measured by 
CyQuant fluorescence (*p<0.05; n=3). 
Figure 8. Proposed mechanisms by which TAS2R agonists induce ASM cell death. TAS2R 
agonists cause up-regulation of Bnip3 expression followed by increased DLP1 mitochondrial 
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localization, mitochondrial dysfunction and cell death, which can be attenuated by Mdivi-1 and 
dominant-negative Bnip3. 
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